Referred to the House Committee on Energy and Commerce.
This bill clarifies that under section 340B of the Public Health Service Act drug manufacturers must offer required discounted pricing for covered outpatient drugs to covered entities regardless of the manner or location in which the drugs are dispensed, including when covered entities use contract pharmacies. It prohibits manufacturers from imposing conditions that limit delivery, purchasing mechanisms, dispensing locations, require submission of claims data, or otherwise single out covered entities, unless those conditions are approved in advance by the Secretary.
Whether statutory clarification and strong penalties are necessary enforcement tools (liberal and centrist view as beneficial; conservatives view as overreach).
Relative to its intended legislative type, this bill is a focused substantive statute that clearly defines its policy goal, integrates changes into existing 340B law, and creates enforceable remedies with explicit rulemaking deadlines.
This bill clarifies that under section 340B of the Public Health Service Act drug manufacturers must offer required discounted pricing for covered outpatient drugs to covered entities regardless of the manner or location in which the drugs are dispensed, including when covered entities use contract pharmacies.
It prohibits manufacturers from imposing conditions that limit delivery, purchasing mechanisms, dispensing locations, require submission of claims data, or otherwise single out covered entities, unless those conditions are approved in advance by the Secretary.
The bill adds explicit protections for contract pharmacy arrangements, creates a process for covered entities to assert claims of violations, requires the Secretary to issue implementing regulations within 180 days, and authorizes civil monetary penalties (up to $2,000,000 per day) for intentional violations other than overcharges, with regulatory standards to be set by the Secretary.
Content-wise the bill addresses a narrowly defined but controversial area of health policy—clarifying 340B access and imposing strong enforcement. It is plausible to pass the House under the right coalition of provider and patient advocates, but it faces meaningful obstacles in the Senate due to potential industry opposition and the need for wider consensus. The absence of compromise features and the high potential litigation/regulatory complexity reduce the overall likelihood unless the measure is softened or attached to a broader negotiated package.
Relative to its intended legislative type, this bill is a focused substantive statute that clearly defines its policy goal, integrates changes into existing 340B law, and creates enforceable remedies with explicit rulemaking deadlines. It balances statutory prescription with delegated regulatory development for detailed standards.
Whether statutory clarification and strong penalties are necessary enforcement tools (liberal and centrist view as beneficial; conservatives view as overreach).
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether statutory clarification and strong penalties are necessary enforcement tools (liberal and centrist view as beneficial; conservatives view as overreach).
A mainstream liberal would likely view this bill as a necessary clarification and enforcement strengthening of the 340B program to protect patient access and preserve safety-net providers’ savings.
They would emphasize that the bill prevents manufacturers from undermining covered entities’ established use of contract pharmacies, and that the civil penalties and a formal claims process strengthen compliance and accountability.
They would see the bill as preserving community health centers’ ability to obtain specialty and other drugs for vulnerable patients.
A centrist/moderate would likely be generally favorable to the bill’s goals of clarifying law and protecting patient access, but concerned about implementation, the scope of penalties, and unintended consequences.
They would value the statutory clarity and enforcement mechanisms but want proportionality, clear standards, and interagency stakeholder consultation to avoid overreach or litigation.
The centrist would weigh benefits to safety-net providers against potential disruption to manufacturer relationships and supply chains, and seek adjustments to reduce regulatory and legal risk.
A mainstream conservative would likely view the bill skeptically as an expansion of federal micromanagement of private pharmaceutical manufacturers and the supply chain.
They would be concerned that the bill restricts manufacturers’ contractual freedom, imposes very large civil penalties, and could lead to higher drug costs or reduced innovation if manufacturers respond by changing business practices.
While acknowledging the importance of patient access, they would prefer market-based or negotiated solutions rather than statutory prohibitions and steep daily fines.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise the bill addresses a narrowly defined but controversial area of health policy—clarifying 340B access and imposing strong enforcement. It is plausible to pass the House under the right coalition of provider and patient advocates, but it faces meaningful obstacles in the Senate due to potential industry opposition and the need for wider consensus. The absence of compromise features and the high potential litigation/regulatory complexity reduce the overall likelihood unless the measure is softened or attached to a broader negotiated package.
The bill has not accumulated any surfaced votes yet.
Whether statutory clarification and strong penalties are necessary enforcement tools (liberal and centrist view as beneficial; conservative…
Content-wise the bill addresses a narrowly defined but controversial area of health policy—clarifying 340B access and imposing strong enfor…
Relative to its intended legislative type, this bill is a focused substantive statute that clearly defines its policy goal, integrates changes into existing 340B law, and creates enforceable remedies with explicit rulem…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.